David M. Langenau

David M. Langenau is a Professor of Pathology at Harvard Medical School and Director of Research Education at Mass General Brigham Pathology. His work focuses on elucidating molecular mechanisms of relapse in pediatric sarcomas and leukemias using zebrafish models, human cell lines, and patient-derived xenografts.

• Institutional Affiliations: Harvard Medical School, Mass General Brigham, Krantz Family Center for Cancer Research, Harvard Stem Cell Institute
• Research Themes: Tumor relapse biology, cancer stem cells, oncogenic pathways, zebrafish avatars, drug discovery

Langenau's research has identified novel combination therapies (e.g., Olaparib-Temozolomide for RMS) and uncovered evolutionarily conserved oncogenic drivers in T-ALL. His team's work bridges zebrafish genetics and clinical translation, including the first zebrafish-origin clinical trial for pediatric cancer.

Selected Research Trends:
Recent publications highlight single-cell transcriptomics in RMS, checkpoint pathways in immunotherapy, and PI3K-AKT-mTOR signaling in T-ALL. These studies integrate bioinformatics, functional assays, and clinical data.

Grants and Collaborations:
His laboratory receives over $19 million annually in research funding and collaborates with institutions like Dana-Farber Cancer Institute and MGH Pathology Service.